Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 5-11, March 2008

Apoptosis in leukemia: From molecular pathways to targeted therapies

  • Aaron D. Schimmer, MD, PhD, FRCPC (Staff Physician and Scientist)

      Affiliations

    • Corresponding Author InformationTel: (416) 946 2838; Fax: (416) 946 6546.

Princess Margaret Hospital, 610 University Ave, Toronto, ON, Canada M5G 2M9

Knowledge about apoptosis pathways developed in the last few years is already being translated into novel targeted therapies. Two illustrative approaches to this process are the development of small molecule BCL2 inhibitors and X-linked inhibitors of apoptosis proteins (XIAP) inhibitors. This work demonstrates both the development of new agents based on molecular mechanisms and how these agents further our understanding of the biology of apoptosis.

Key words: apoptosis, caspase, inhibitors, BCL2, XIAP, X-linked inhibitors of apoptosis protein, targeted therapies

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by the Canadian Institutes of Health Research (CIHR), and the Canadian Cancer Society. A.D.S. is the recipient of a CIHR Clinician Scientist Award.

PII: S1521-6926(07)00091-6

doi:10.1016/j.beha.2007.11.002

Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 5-11, March 2008